Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Pauline Hulo
Observed names:
Hulo, Pauline,
P. Hulo
Institutions:
Centre Hospitalier Universitaire de Nantes,
Université de Nantes,
Nantes Université
Observed institutions:
Centre National de la Recherche Scientifique,
Inserm,
Centre Hospitalier Universitaire de Nantes,
Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers,
Clinique Mutualiste de l'Estuaire,
Université de Nantes,
Université d'Angers,
Nantes Université
show all 8
ORCID:
0000-0003-0675-6215
Observed ORCID:
0000-0003-0675-6215
OpenAlex ID:
A5000784040
Predictive factors of splanchnic vein thrombosis in acute pancreatitis: A 6‐year single‐center experience
2015
·
Laurence Toqué
, Antoine Hamy
, et al.
·
Journal of Digestive Diseases
·
47
Pembrolizumab for the treatment of colorectal cancer
2020
·
Dahna Coupez
, Pauline Hulo
, et al.
·
Expert Opinion on Biological Therapy
·
33
Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%
2023
·
E. Pons-Tostivint
, P. Hulo
, et al.
·
Cancer Immunology Immunotherapy
·
27
PDF
Acute Ulceronecrotic Gastritis With Cytomegalovirus Reactivation: Uncommon Toxicity of Immune Checkpoint Inhibitors in Microsatellite Instability–High Metastatic Colorectal Cancer
2020
·
Pauline Hulo
, Yann Touchefeu
, et al.
·
Clinical Colorectal Cancer
·
18
PDF
EGFR mutation-positive NSCLC: factors to consider when deciding first-line therapy
2020
·
Pauline Hulo
, Dahna Coupez
, et al.
·
Expert Review of Anticancer Therapy
·
15
Use of non-small cell lung cancer multicellular tumor spheroids to study the impact of chemotherapy
2024
·
Pauline Hulo
, Sophie Deshayes
, et al.
·
Respiratory Research
·
10
PDF
KRAS mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicine
2021
·
Dahna Coupez
, Pauline Hulo
, et al.
·
Expert Opinion on Biological Therapy
·
9
Pneumopathies interstitielles diffuses induites par les anticorps conjugués
2025
·
L. Maurier
, A.-L. Chéné
, et al.
·
Revue des Maladies Respiratoires
·
5
Carcinoembryonic Antigen Increase in a Patient with Colon Cancer Who Have Achieved Complete Remission and Negative 18F-FDG PET/CT: Don’t Forget the Thyroid!
2021
·
Alexandre Lugat
, Pauline Hulo
, et al.
·
Current Oncology
·
4
PDF
Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib
2025
·
Pascale Tomasini
, Oscar Juan-Vidal
, et al.
·
Clinical Lung Cancer
·
3
Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%
2023
·
E. Pons-Tostivint
, P. Hulo
, et al.
·
Cancer Immunology Immunotherapy
·
3
PDF
411P: Tumor miRNAs in small-extracellular vesicles dampen the CD8+ T cell response against tumor and predict response to immunotherapy in NSCLC
2025
·
M. Chang
, V. Dehame
, et al.
·
Journal of Thoracic Oncology
·
1
PDF
Concomitant ALK translocation and EGFR C797S mutation as resistance mechanisms to osimertinib in an EGFR-mutant NSCLC patient
2024
·
Elvire Pons-Tostivint
, Pauline Hulo
, et al.
·
Respiratory Medicine and Research
·
1
Enquête nationale auprès des infirmiers en pratique avancée mention oncologie-hématologie : évaluation de l’activité et de la formation continue
2024
·
Elvire Pons-Tostivint
, Laure De Decker
, et al.
·
Bulletin du Cancer
·
1
PDF
147O Scope of NUT carcinomas (NC): An international multicentric study
2024
·
M.V. Sanchez Becerra
, M. Knetki-Wroblewska
, et al.
·
ESMO Open
·
1
PDF
8P Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutant advanced NSCLC after progression on osimertinib: Secondary analyses of patient-relevant endpoints from MARIPOSA-2
2024
·
P. Tomasini
, A. Blasco Cordellat
, et al.
·
ESMO Open
·
1
Évaluation du retour au travail après un traitement systémique pour un cancer pulmonaire non à petites cellules
2026
·
Marie Cap
, Virginie Nael
, et al.
·
Bulletin du Cancer
Abstract 5996: New therapeutic approaches in NUT carcinoma: An unmet need
2025
·
Maria Virginia Sanchez-Becerra
, Carmen Escudero-Iriarte
, et al.
·
Cancer Research
Évaluation du retour au travail des patients ayant reçu un traitement systémique pour un cancer pulmonaire non à petites cellules
2025
·
M. Cap
, L. Fourage
, et al.
·
Revue des Maladies Respiratoires Actualités
The BREATHE project: An observational prospective cohort integrating clinical data, blood samples and tumor tissue from newly diagnosed patients with lung cancer
2024
·
Elvire Pons-Tostivint
, Marc Grégoire Denis
, et al.
·
Research Square
PDF
9P Small-extracellular vesicles derived from NSCLC cells dampen the CD8+ T cell response against tumor
2024
·
M. Chang
, V. Dehame
, et al.
·
Annals of Oncology
PDF
EP16.04-019 Impact of Chemotherapy on Tridimensional Multicellular Non-small Cell Lung Cancer Spheroids with Microenvironment Cells
2022
·
P. Hulo
, S. Deshayes
, et al.
·
Journal of Thoracic Oncology
1113P Real-world multicentre cohort of 1L pembrolizumab alone or in combination with platinum-based chemotherapy in NSCLC PD-L1 ≥ 50%
2022
·
E. Pons-Tostivint
, P. Hulo
, et al.
·
Annals of Oncology
PDF
66P Incidence and impact on survival of venous thromboembolic events in patients with advanced non-small cell lung cancer receiving pembrolizumab as first-line of treatment
2022
·
P. Hulo
, H. Senellart
, et al.
·
Annals of Oncology
PDF
Abstract 319: Impact of chemotherapy on lung cancer cells and their microenvironment, evaluated in tridimensional multicellular tumor spheroids
2020
·
Pauline Hulo
, Sophie Deshayes
, et al.
·
Cancer Research
Show more works
View as search
Works count:
36
Citation count:
179
H-index:
7
I10-index:
6
Year
Topic
Type